Marshall Wace LLP Grows Holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

Marshall Wace LLP boosted its position in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 4,422.4% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 456,762 shares of the biotechnology company's stock after acquiring an additional 446,662 shares during the quarter. Marshall Wace LLP owned about 0.50% of Rocket Pharmaceuticals worth $5,741,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the company. Wellington Management Group LLP boosted its holdings in Rocket Pharmaceuticals by 24.5% in the fourth quarter. Wellington Management Group LLP now owns 13,995,177 shares of the biotechnology company's stock valued at $175,919,000 after purchasing an additional 2,753,033 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Rocket Pharmaceuticals by 18.8% in the fourth quarter. Vanguard Group Inc. now owns 6,577,595 shares of the biotechnology company's stock worth $82,680,000 after buying an additional 1,040,655 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in Rocket Pharmaceuticals during the fourth quarter worth about $2,747,000. ADAR1 Capital Management LLC raised its position in Rocket Pharmaceuticals by 4,816.3% during the fourth quarter. ADAR1 Capital Management LLC now owns 211,400 shares of the biotechnology company's stock valued at $2,657,000 after acquiring an additional 207,100 shares in the last quarter. Finally, Ovata Capital Management Ltd purchased a new position in Rocket Pharmaceuticals during the fourth quarter valued at approximately $2,514,000. Hedge funds and other institutional investors own 98.39% of the company's stock.

Rocket Pharmaceuticals Price Performance

Shares of NASDAQ RCKT traded up $0.06 during mid-day trading on Tuesday, reaching $7.22. The company's stock had a trading volume of 304,628 shares, compared to its average volume of 1,327,148. The company has a debt-to-equity ratio of 0.06, a quick ratio of 6.05 and a current ratio of 6.05. The stock has a 50-day moving average of $7.57 and a two-hundred day moving average of $11.25. The stock has a market capitalization of $769.34 million, a P/E ratio of -2.63 and a beta of 1.00. Rocket Pharmaceuticals, Inc. has a 1-year low of $4.55 and a 1-year high of $26.98.

Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) last released its quarterly earnings results on Monday, March 3rd. The biotechnology company reported ($0.62) earnings per share for the quarter, topping analysts' consensus estimates of ($0.68) by $0.06. On average, equities research analysts anticipate that Rocket Pharmaceuticals, Inc. will post -2.83 EPS for the current fiscal year.

Insider Transactions at Rocket Pharmaceuticals

In other news, CFO Aaron Ondrey sold 7,489 shares of the firm's stock in a transaction dated Friday, April 4th. The stock was sold at an average price of $5.29, for a total transaction of $39,616.81. Following the sale, the chief financial officer now owns 129,650 shares of the company's stock, valued at approximately $685,848.50. This trade represents a 5.46 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Gaurav Shah bought 20,000 shares of the business's stock in a transaction dated Thursday, April 10th. The shares were purchased at an average price of $5.08 per share, for a total transaction of $101,600.00. Following the transaction, the chief executive officer now directly owns 792,680 shares of the company's stock, valued at approximately $4,026,814.40. This represents a 2.59 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 28.50% of the company's stock.

Analysts Set New Price Targets

RCKT has been the topic of a number of analyst reports. Scotiabank raised their price objective on shares of Rocket Pharmaceuticals from $51.00 to $52.00 and gave the stock a "sector outperform" rating in a research note on Monday, March 3rd. BMO Capital Markets initiated coverage on shares of Rocket Pharmaceuticals in a report on Wednesday, March 12th. They issued an "outperform" rating and a $50.00 price objective for the company. Needham & Company LLC reissued a "buy" rating and set a $42.00 target price on shares of Rocket Pharmaceuticals in a research note on Wednesday, April 9th. The Goldman Sachs Group cut their price target on Rocket Pharmaceuticals from $29.00 to $15.00 and set a "neutral" rating for the company in a research note on Monday, March 3rd. Finally, Canaccord Genuity Group cut their price objective on Rocket Pharmaceuticals from $39.00 to $36.00 and set a "buy" rating for the company in a research report on Monday, March 3rd. One investment analyst has rated the stock with a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat, Rocket Pharmaceuticals has an average rating of "Moderate Buy" and a consensus price target of $43.00.

Rocket Pharmaceuticals Profile

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.